After years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech.
The company is looking to raise just $150 million in an initial public offering, according to a registration statement filed with the Securities and Exchange Commission on Wednesday.
About the Author Reprints
